R.M. Abra

1.4k total citations
29 papers, 1.1k citations indexed

About

R.M. Abra is a scholar working on Biomaterials, Molecular Biology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, R.M. Abra has authored 29 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Biomaterials, 14 papers in Molecular Biology and 6 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in R.M. Abra's work include Nanoparticle-Based Drug Delivery (15 papers), RNA Interference and Gene Delivery (8 papers) and Radiopharmaceutical Chemistry and Applications (5 papers). R.M. Abra is often cited by papers focused on Nanoparticle-Based Drug Delivery (15 papers), RNA Interference and Gene Delivery (8 papers) and Radiopharmaceutical Chemistry and Applications (5 papers). R.M. Abra collaborates with scholars based in United States, United Kingdom and Israel. R.M. Abra's co-authors include C. Anthony Hunt, Anthony H. C. Huang, Jan Vaage, Peter K. Working, Peter J. Quinn, Paul S. Uster, Emilio Barberá‐Guillem, Kevin J. Harrington, Konstantinos N. Syrigos and Gail Rowlinson‐Busza and has published in prestigious journals such as Cancer, Biochemical Journal and Journal of Controlled Release.

In The Last Decade

R.M. Abra

29 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
R.M. Abra United States 19 509 498 215 212 200 29 1.1k
Bela Kaufman Israel 6 546 1.1× 644 1.3× 280 1.3× 349 1.6× 95 0.5× 7 1.3k
Alberto Gabizon Israel 16 754 1.5× 840 1.7× 342 1.6× 356 1.7× 106 0.5× 23 1.6k
Judith Senior United Kingdom 12 842 1.7× 609 1.2× 122 0.6× 165 0.8× 78 0.4× 16 1.3k
Dawn Waterhouse Canada 20 704 1.4× 568 1.1× 308 1.4× 360 1.7× 76 0.4× 36 1.4k
Takanori Kawaguchi Japan 22 588 1.2× 202 0.4× 331 1.5× 131 0.6× 250 1.3× 77 1.5k
S S Burtles United Kingdom 12 408 0.8× 541 1.1× 185 0.9× 304 1.4× 56 0.3× 17 1.1k
N. Willmott United Kingdom 20 458 0.9× 221 0.4× 391 1.8× 85 0.4× 152 0.8× 64 1.3k
Colin F. Greineder United States 24 522 1.0× 373 0.7× 154 0.7× 256 1.2× 253 1.3× 66 1.5k
Aquilur Rahman United States 22 608 1.2× 598 1.2× 557 2.6× 173 0.8× 92 0.5× 48 1.4k
Olivier Meyer United States 10 882 1.7× 798 1.6× 182 0.8× 379 1.8× 70 0.3× 17 1.6k

Countries citing papers authored by R.M. Abra

Since Specialization
Citations

This map shows the geographic impact of R.M. Abra's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R.M. Abra with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R.M. Abra more than expected).

Fields of papers citing papers by R.M. Abra

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R.M. Abra. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R.M. Abra. The network helps show where R.M. Abra may publish in the future.

Co-authorship network of co-authors of R.M. Abra

This figure shows the co-authorship network connecting the top 25 collaborators of R.M. Abra. A scholar is included among the top collaborators of R.M. Abra based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R.M. Abra. R.M. Abra is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Arčon, Iztok, et al.. (2003). EXAFS study of liposome-encapsulated cisplatin. Colloids and Surfaces B Biointerfaces. 33(3-4). 199–204. 8 indexed citations
2.
Gabizón, Alberto, Aviva T. Horowitz, Dinah Tzemach, et al.. (2002). Folate receptor targeting of pegylated liposomal cisplatin enhances anti-tumor activity in mouse models without increasing toxicity. 43. 415. 2 indexed citations
3.
Abra, R.M., Richard B. Bankert, Fa Chen, et al.. (2002). THE NEXT GENERATION OF LIPOSOME DELIVERY SYSTEMS: RECENT EXPERIENCE WITH TUMOR-TARGETED, STERICALLY-STABILIZED IMMUNOLIPOSOMES AND ACTIVE-LOADING GRADIENTS. Journal of Liposome Research. 12(1-2). 1–3. 43 indexed citations
4.
Peleg‐Shulman, Tal, et al.. (2001). Characterization of sterically stabilized cisplatin liposomes by nuclear magnetic resonance. Biochimica et Biophysica Acta (BBA) - Biomembranes. 1510(1-2). 278–291. 67 indexed citations
5.
Harrington, Kevin J., Gail Rowlinson‐Busza, Konstantinos N. Syrigos, et al.. (2000). Influence of tumour size on uptake of111In-DTPA-labelled pegylated liposomes in a human tumour xenograft model. British Journal of Cancer. 83(5). 684–688. 74 indexed citations
6.
Harrington, Kevin J., Gail Rowlinson‐Busza, Konstantinos N. Syrigos, et al.. (2000). Biodistribution and pharmacokinetics of 111In-DTPA-labelled pegylated liposomes in a human tumour xenograft model: implications for novel targeting strategies. British Journal of Cancer. 83(2). 232–238. 76 indexed citations
7.
Vaage, Jan, et al.. (1999). Therapy of a xenografted human colonic carcinoma using cisplatin or doxorubicin encapsulated in long-circulating pegylated stealth liposomes. International Journal of Cancer. 80(1). 134–137. 40 indexed citations
8.
Vaage, Jan, Emilio Barberá‐Guillem, R.M. Abra, Anthony H. C. Huang, & Peter K. Working. (1994). Tissue distribution and therapeutic effect of intravenous free or encapsulated liposomal doxorubicin on human prostate carcinoma xenografts. Cancer. 73(5). 1478–1484. 133 indexed citations
9.
Ning, Shoucheng, et al.. (1994). Hyperthermia induces doxorubicin release from long-circulating liposomes and enhances their anti-tumor efficacy. International Journal of Radiation Oncology*Biology*Physics. 29(4). 827–834. 57 indexed citations
10.
11.
Vaage, Jan, et al.. (1993). Therapy of human ovarian carcinoma xenografts using doxorubicin encapsulated in sterically stabilized liposomes. Cancer. 72(12). 3671–3675. 83 indexed citations
12.
Fielding, Robert M. & R.M. Abra. (1992). Factors Affecting the Release Rate of Terbutaline from Liposome Formulations After Intratracheal Instillation in the Guinea Pig. Pharmaceutical Research. 9(2). 220–223. 32 indexed citations
13.
Pettenazzo, Andrea, et al.. (1989). Clearance of Phosphatidylcholine and Cholesterol from Liposomes, Liposomes Loaded with Metaproterenol, and Rabbit Surfactant from Adult Rabbit Lungs. American Review of Respiratory Disease. 139(3). 752–758. 41 indexed citations
14.
Schreier, Hans, R.M. Abra, John Kaplan, & C. Anthony Hunt. (1987). Murine plasma fibronectin depletion after intravenous injection of liposomes. International Journal of Pharmaceutics. 37(3). 233–238. 8 indexed citations
15.
Abra, R.M., et al.. (1984). Liposome Disposition In Vivo VI: Delivery to the Lung. Journal of Pharmaceutical Sciences. 73(2). 203–206. 51 indexed citations
16.
Abra, R.M., C. Anthony Hunt, K.K. Fu, & J.H. Peters. (1983). Delivery of therapeutic doses of doxorubicin to the mouse lung using lung-accumulating liposomes proves unsuccessful. Cancer Chemotherapy and Pharmacology. 11(2). 98–101. 5 indexed citations
17.
Abra, R.M. & C. Anthony Hunt. (1981). Liposome disposition in vivo. Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism. 666(3). 493–503. 204 indexed citations
18.
Abra, R.M., et al.. (1980). Liposome disposition in vivo: effects of pre-dosing with lipsomes.. PubMed. 29(2). 349–60. 29 indexed citations
19.
Abra, R.M., et al.. (1980). The growth of micro-organisms in some parenteral radiopharmaceuticals. International Journal of Pharmaceutics. 5(3). 187–193. 2 indexed citations
20.
Abra, R.M. & Peter J. Quinn. (1976). Some characteristics of sn-glycero-3-phosphocholine diesterases from rat brain. Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism. 431(3). 631–639. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Bela Kaufman Breakdown of academic impact, for papers by Alberto Gabizon Breakdown of academic impact, for papers by Judith Senior Breakdown of academic impact, for papers by Dawn Waterhouse Breakdown of academic impact, for papers by Takanori Kawaguchi Breakdown of academic impact, for papers by S S Burtles Breakdown of academic impact, for papers by N. Willmott Breakdown of academic impact, for papers by Colin F. Greineder Breakdown of academic impact, for papers by Aquilur Rahman Breakdown of academic impact, for papers by Olivier Meyer
Rankless by CCL
2026